KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBITDA Margin (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed EBITDA Margin for 6 consecutive years, with 304.84% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 373755.0% year-over-year to 304.84%, compared with a TTM value of 867.87% through Dec 2025, down 7159.0%, and an annual FY2025 reading of 867.87%, down 5377.0% over the prior year.
  • EBITDA Margin was 304.84% for Q4 2025 at Recursion Pharmaceuticals, up from 3327.57% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 304.84% in Q4 2025 and bottomed at 4042.39% in Q4 2024.
  • Average EBITDA Margin over 5 years is 1232.35%, with a median of 895.73% recorded in 2023.
  • The sharpest move saw EBITDA Margin soared 2938181bps in 2021, then crashed -313402bps in 2024.
  • Year by year, EBITDA Margin stood at 2564.55% in 2021, then skyrocketed by 83bps to 445.91% in 2022, then crashed by -104bps to 908.36% in 2023, then plummeted by -345bps to 4042.39% in 2024, then skyrocketed by 92bps to 304.84% in 2025.
  • Business Quant data shows EBITDA Margin for RXRX at 304.84% in Q4 2025, 3327.57% in Q3 2025, and 916.75% in Q2 2025.